Development and validation of an ankle brachial index risk model for the prediction of cardiovascular events by Fowkes, FGR et al.
Development and validation of an ankle brachial index risk 
model for the prediction of cardiovascular events
FGR Fowkes1,*, GD Murray1,*, I Butcher1,*, AR Folsom2, AT Hirsch3, DJ Couper4, G 
DeBacker5, M Kornitzer6, AB Newman7, KC Sutton-Tyrrell7, M Cushman8, AJ Lee9, JF 
Price1, RB D’Agostino Sr10, JM Murabito11, PE Norman12, KH Masaki13, LM Bouter14, RJ 
Heine15, CDA Stehouwer16, MM McDermott17, HEJH Stoffers18, JA Knottnerus18, M 
Ogren19, B Hedblad20, W Koenig21, C Meisinger22, JA Cauley7, OH Franco23, MGM 
Hunink23, A Hofman23, JC Witteman23, MH Criqui24, RD Langer25, WR Hiatt26, RF 
Hamman27, and Ankle Brachial Index Collaboration
1Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK 2Division of 
Epidemiology and Community Health, University of Minnesota, Minneapolis, MN, USA 
3Cardiovascular Division, Lillehei Heart Institute, University of Minnesota Medical School, 
Minneapolis, MN, USA 4Department of Biostatistics, University of North Carolina, Chapel Hill, NC, 
USA 5Department of Public Health, Ghent University, Ghent, Belgium 6School of Public Health, 
Universite Libre de Bruxelles, Brussels, Belgium 7Department of Epidemiology, Graduate School 
of Public Health, University of Pittsburgh, Pittsburgh, PA, USA 8Department of Medicine, 
University of Vermont, Burlington, VT, USA 9Section of Population Health, University of 
Aberdeen, Aberdeen, UK 10Mathematics and Statistics Department, Boston University, Boston, 
MA, USA 11Department of Medicine, Boston University School of Medicine, Boston, MA, USA 
12School of Surgery, University of Western Australia, Perth, Australia 13Department of Geriatric 
Medicine, John A Burns School of Medicine, University of Hawaii, Honolulu, HI, USA 14Executive 
Board, VU University Amsterdam, Amsterdam, Netherlands 15Diabetes Center, VU University 
Medical Center, Amsterdam, Netherlands 16Department of Internal Medicine, Maastricht 
University Medical Centre, Maastricht, Netherlands 17Department of Medicine, Northwestern 
University Feinberg School of Medicine, Chicago, IL, USA 18Department of General Practice/
Family Medicine, CAPHRI School for Public Health and Primary Care, Maastricht University 
Medical Centre, Maastricht, Netherlands 19Department of Surgical Sciences (Vascular Surgery), 
Uppsala University, Uppsala, Sweden 20Department of Clinical Sciences, Skane University 
Hospital, Lund University, Malmo, Sweden 21Department of Internal Medicine II – Cardiology, 
University of Ulm Medical Center, Ulm, Germany 22Institute of Epidemiology II, Helmholtz 
Zentrum Munchen, Neuherberg, Germany 23Department of Epidemiology, Erasmus MC, 
Rotterdam, Netherlands 24Department of Family and Preventive Medicine, University of California 
San Diego, La Jolla, CA, USA 25Department of Family Medicine – Las Vegas, University of 
Reprints and permissions: sagepub.co.uk/journalsPermissions.nav
Corresponding author: FGR Fowkes, Centre for Population Health Sciences, University of Edinburgh, Edinburgh, EH8 9AG, UK. 
Gerry.Fowkes@ed.ac.uk.
*These authors have contributed equally.
Conflict of interest
The authors declare that there is no conflict of interest.
HHS Public Access
Author manuscript
Eur J Prev Cardiol. Author manuscript; available in PMC 2015 December 21.
Published in final edited form as:













Nevada School of Medicine, Las Vegas, NV, USA 26Department of Medicine/Cardiology, 
University of Colorado School of Medicine, Aurora, CO, USA 27Department of Epidemiology, 
Colorado School of Public Health, Aurora, CO, USA
Abstract
Background—The ankle brachial index (ABI) is related to risk of cardiovascular events 
independent of the Framingham risk score (FRS). The aim of this study was to develop and 
evaluate a risk model for cardiovascular events incorporating the ABI and FRS.
Design—An analysis of participant data from 18 cohorts in which 24,375 men and 20,377 
women free of coronary heart disease had ABI measured and were followed up for events.
Methods—Subjects were divided into a development and internal validation dataset and an 
external validation dataset. Two models, comprising FRS and FRS + ABI, were fitted for the 
primary outcome of major coronary events.
Results—In predicting events in the external validation dataset, C-index for the FRS was 0.672 
(95% CI 0.599 to 0.737) in men and 0.578 (95% CI 0.492 to 0.661) in women. The FRS + ABI led 
to a small increase in C-index in men to 0.685 (95% CI 0.612 to 0.749) and large increase in 
women to 0.690 (95% CI 0.605 to 0.764) with net reclassification improvement (NRI) of 4.3% 
(95% CI 0.0 to 7.6%, p = 0.050) and 9.6% (95% CI 6.1 to 16.4%, p < 0.001), respectively. 
Restricting the FRS + ABI model to those with FRS intermediate 10-year risk of 10 to 19% 
resulted in higher NRI of 15.9% (95% CI 6.1 to 20.6%, p < 0.001) in men and 23.3% (95% CI 
13.8 to 62.5%, p = 0.002) in women. However, incorporating ABI in an improved newly fitted 
risk factor model had a nonsignificant effect: NRI 2.0% (95% CI 2.3 to 4.2%, p = 0.567) in men 
and 1.1% (95% CI 1.9 to 4.0%, p = 0.483) in women.
Conclusions—An ABI risk model may improve prediction especially in individuals at 
intermediate risk and when performance of the base risk factor model is modest.
Keywords
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Introduction
The accurate prediction of major cardiovascular events in individuals without vascular 
disease is an important public health goal, allowing targeting of preventive measures to 
those at increased risk. The Framingham risk score (FRS), which combines classic 
cardiovascular risk factors such as cigarette smoking and total cholesterol, is the most well-
known method of risk prediction. However, the FRS has limited accuracy1, and attempts 
have been made to improve prediction by incorporating additional risk factors, novel 
biomarkers, and measures of subclinical atherosclerosis.2
The ankle brachial index (ABI), which is the ratio of ankle:arm systolic pressure, is a 
measure of atherosclerosis in symptomatic and asymptomatic individuals. Originally 
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developed as a diagnostic tool for leg artery disease, the ABI is also an indicator of 
generalized atherosclerosis and of future cardiovascular events, independent of established 
risk factors.3 Since the ABI can be measured using only a handheld Doppler probe and 
sphygmomanometer in many healthcare settings, the possibility of using the ABI to enhance 
risk prediction is of interest.
The ABI Collaboration was formed of investigators performing longitudinal studies of the 
ABI and incident cardiovascular events. In a meta-analysis comprising 48,294 subjects, a 
low ABI (≤0.90) compared to a normal ABI (1.11–1.40) was related to a 2–3-fold increase 
in both 10-year major coronary events and cardiovascular mortality independent of the FRS.
3 Furthermore, in cardiovascular risk stratification using the FRS, subsequent inclusion of 
the ABI resulted in reclassification of risk (low, intermediate, high) in 1 in 5 men and 1 in 3 
women. However, the impact of reclassification in improving risk prediction was not 
assessed.
In this present study, our aim was to develop an ABI prediction model incorporating FRS 
and ABI into a single equation. The ABI model was then evaluated in a different population 
and the effect of reclassification of 10-year risk assessed. Since risk prediction varies 
according to gender and ethnic group,4 the model was developed separately in men and 




The study design was an analysis of individual participant data from 18 prospective cohort 
studies. Risk prediction models were fitted in a development dataset and evaluated in 
internal and external validation datasets.
Inclusion and exclusion of studies
The study was based on 20 cohort datasets in the ABI Collaboration. The literature search 
and collation of data from 16 of these studies5–20 were described previously.3 Since then, 
experts informed us of four further studies,21–24 from which corresponding data were 
acquired. Two studies included only non-White ethnic groups7,8 and were excluded, leaving 
18 studies in the final analysis. Individual participant data were extracted and analysed using 
version 9.2 of SAS System for Windows (2002–2008; SAS Institute, Cary, NC, USA).
Subjects, variables, and missing data
Subjects with nonvalid ABI, with prevalent coronary heart disease as defined in each study 
at baseline, and without follow up for vital status were excluded. Framingham covariates 
extracted were age, gender, systolic and diastolic blood pressures, total and high-density 
lipoprotein cholesterol, and smoking and diabetes indicators. ABI, study location, and ethnic 
group were obtained and only subjects included who were classified as ‘white’ using 
individual study classifications. Analyses were not performed on non-White ethnic groups 
because of small sample sizes. The numbers of men and women in the final analysis were 
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24,375 and 20,377, respectively. Only 7.4% of data in men and 2.9% in women were 
missing, predominantly for total and high-density lipoprotein cholesterol. Imputation was 
performed separately by gender using the SAS procedure PROC MI with the MCMC full-
data imputation method. FRS was calculated for all individuals using the methods of Wilson 
et al.25 In keeping with our previous investigation,3 ABI was categorized into four groups: 
≤0.90, 0.91–1.10, 1.11–1.40, >1.40.
Development, internal validation, and external validation datasets
The studies were divided into two groups separately by gender to create, first, a model 
development and internal validation dataset and, secondly, an external validation dataset. 
Studies were allocated to these datasets based on study location (USA or not), earlier vs. 
later start date, larger vs. smaller study, age range of participants, and median duration of 
follow up in order to achieve a balance across datasets. Studies with one or more wholly 
imputed covariates were constrained to be in the external validation dataset. The 
characteristics of the studies are shown in Table 1. The first dataset was then divided in two 
by randomly selecting half the participants in each study. Prediction models were fitted in 
the first half (development dataset) and validated in the other half (internal validation 
dataset) and finally in the external validation dataset.
Model fitting
Two models were fitted each for the primary outcome of major coronary events (myocardial 
infarction or death due to coronary heart disease) and the secondary outcome of 
cardiovascular mortality (death due to coronary heart disease or stroke) using Cox’s 
proportional hazards model, as follows: model 1: Framingham risk score25 fitted as a 
continuous variable (FRS); model 2: as per model 1 with addition of ABI group (FRS + 
ABI).
These models were first fitted for men and women separately in the development datasets. 
Details of the fitted FRS + ABI for major coronary events are shown in Supplementary 
Table 1 and measures of model performance26–28 in Supplementary Table 2 (available 
online).
For comparison with the FRS, an additional risk factor model was fitted in the development 
dataset in which, instead of using the overall single FRS value, each individual Framingham 
risk covariate, such as smoking, was used separately. And then a further model was fitted 
with addition of ABI group (Supplementary Table 1). Assumptions for Cox’s analyses were 
checked formally.
Outcome measures
To quantify the effect of inclusion of the ABI in risk prediction models, the C-index and net 
reclassification improvement (NRI) were derived.
The C-index is analogous to C-statistic, which is the area under the receiver operating 
characteristic curve and is a measure of the model’s discrimination of events and non-
events. The C-index is for survival data, being the fraction of occasions where the predictor 
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score correctly predicts the earlier event for pairs of individuals in the sample. This was 
achieved using the methods of Harrell et al.29 and Pencina and D’Agostino30 adopting the 
simplified method for confidence intervals.
For the calculation of the NRI, reclassification tables comparing predicted risk categories for 
models with and without ABI were constructed for the external validation dataset. Ten-year 
risk categories of <10%, 10–19%, and ≥20% were selected for major coronary events and 
<2%, 2–4%, and ≥5% for cardiovascular mortality. NRIs were calculated taking account of 
censored data.31 Confidence intervals and p-values were derived using methods for the 
standard NRI.
For major coronary events, analysis was repeated with a wider intermediate group of 5–
19%, akin to some recent studies of risk prediction.32,33
Results
Predicting events in the whole study population
Table 2 shows that C-indices in the internal validation dataset were mostly similar to those 
in the development dataset but in the external validation dataset were mostly lower. In the 
latter, C-indices for the FRS in men were 0.672 (95% CI 0.599 to 0.737) for major coronary 
events and 0.684 (95% CI 0.625 to 0.738) for cardiovascular mortality, and in women were 
particularly low: 0.578 (95% CI 0.492 to 0.661) and 0.449 (95% CI 0.377 to 0.523), 
respectively. Incorporation of the ABI led to a modest increase in the C-index for men to 
0.685 (95% CI 0.605 to 0.764) for major coronary events and 0.710 (95% CI 0.652 to 0.762) 
for cardiovascular mortality. However, in women, the increase was much larger, to 0.690 
(95% CI 0.605 to 0.764) for major coronary events and 0.652 (95% CI 0.579 to 0.719) for 
cardiovascular mortality so that the C-indices approximated more closely to those of men.
The effect of the FRS + ABI model on prediction, in comparison to the FRS, is shown in 
Figure 1 according to low, intermediate, and high 10-year risk for a major coronary event. 
Within each FRS risk category, the FRS+ABI model refined the degree of risk 
corresponding to trends in event rates (except for a low event rate in women classified at 
intermediate risk of 10–19% by both models).
The impact of reclassification of risk using the FRS + ABI model compared to the FRS is 
shown in Table 3. For major coronary events, the NRI was 4.3% (95% CI 0.0 to 7.6%, 
p=0.050) in men and 9.6% (95% CI 6.1 to 16.4%, p < 0.001) in women and included a net 
increase in risk category in those having an event. For cardiovascular mortality, the NRI was 
5.7% (95% CI 2.7 to 7.9%, p < 0.001) in men and 15.7% (95% CI 11.3 to 20.2%, p < 0.001) 
in women in whom improved classification occurred in those having and not having a 
cardiovascular death. Detailed reclassification data for the primary outcome of major 
coronary events are shown in Supplementary Table 3 and Supplementary Table 4.
Predicting events in subjects at intermediate risk
Restricting use of the ABI model to only those at intermediate 10-year FRS risk had a 
greater effect (Table 4) than in all subjects. In those with a 10–19% risk for a major 
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coronary event, incorporation of the ABI resulted in a NRI of 15.9% (95% CI 6.1 to 20.6%, 
p < 0.001) in men and 23.3% (95% CI 13.8 to 62.5%, p = 0.002) in women. This was due to 
a net increase in subjects having an event reclassified as higher risk and in those not having 
an event reclassified as lower risk. In restricting use of the ABI to those at intermediate 10-
year risk of 2–4% for cardiovascular death, NRIs were likewise higher than in the whole 
population but were similar in men and women: 20.2% (95% CI 11.5 to 29.1%, p < 0.001) 
and 18.0% (95% CI 13.1 to 22.9%, p < 0.001), respectively.
The impact of reclassification on major coronary events using the FRS + ABI model was 
analysed using a wider FRS intermediate 10-year risk category of 5–19% (Supplementary 
Tables 5 and 6). This categorization resulted in very few numbers in the <5% risk group. In 
the whole population, the NRI for men was modest (3.1% (95% CI 0.6 to 6.4%, p = 0.018)) 
but for women was considerable (20.4% (95% CI 11.6 to 22.5%, p < 0.001)), with improved 
net reclassification for those having and not having an event. Restricting the FRS + ABI 
model to the 5–19% intermediate group led to a higher NRI in men (7.9% (95% CI 3.7 to 
11.5%, p < 0.001)) but a lower NRI in women (13.0% (95% CI 7.3 to 17.9%, p < 0.001)).
Predicting events using cardiovascular risk covariate model
C-indices for the newly developed risk factor model in predicting major coronary events in 
the external validation dataset were 0.683 (95% CI 0.611 to 0.748) in men and 0.788 (95% 
CI 0.709 to 0.850) in women, which were slightly higher in men and considerably higher in 
women than the corresponding FRS C-indices in Table 2. Incorporation of the ABI resulted 
in only a slight improvement, increasing C-indices to 0.690 (95% CI 0.618 to 0.754) in men 
and 0.791(95% CI 0.712 to 0.852) in women, with nonsignificant NRIs of 2.0% (95% CI –
2.3 to 4.2%, p=0.567) and 1.1% (95% CI –1.9 to 4.0%, p = 0.483), respectively. In only 
those at intermediate 10–19% risk, NRIs were 7.7% (95% CI 0.0 to 13.0%, p=0.049) in men 
and 2.4% (95% CI –3.0 to 10.5%, p = 0.275) in women.
Discussion
Main findings
In this analysis combining data from 18 population-based studies, a new ABI risk model 
incorporating the FRS+ABI was developed and then validated in an external population. In 
comparison to the FRS, as measured by C-index and NRI, the ABI model led to an 
improvement in performance, but mostly in women. Restricting use of the ABI model to 
those at intermediate 10-year risk of 10–19% for major coronary events resulted in higher 
NRIs than in the whole population. In a wider intermediate risk group of 5–19%, the NRIs 
were lower than in the 10–19% risk group.
The more impressive results in women than in men might be related to the particularly poor 
performance of the FRS in women in the external validation dataset in which C-indices were 
much lower than in the development and internal validation datasets (Table 2). This may 
have been due to chance or unexpected population differences. The main effect of 
incorporating the ABI may have been to compensate for this poor performance by bringing 
the C-indices up towards those of men and not that the ABI model was inherently superior 
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in women than in men. When a better performing model based on fitting individual risk 
covariates was used instead of the FRS, incorporation of the ABI in the prediction of major 
coronary events led to no significant improvement. These results suggest that the impact of 
the ABI is not a fixed phenomenon but is influenced by how well the base risk factor model 
performs.
Other studies
The Multi-Ethnic Study of Atherosclerosis (MESA) found that the ABI contributed to an 
improvement in classification of cardiovascular events and non-events compared to 
traditional risk factors as measured by integrated discrimination improvement.34 In the 
Atherosclerosis Risk in Communities (ARIC) Study and Rotterdam Study, each components 
of the ABI Collaboration, the effect on prediction of adding the ABI to a cardiovascular risk 
equation was examined32,35 and found, in the whole study populations, to have minimal 
impact. In keeping with the present study, both the ARIC and Rotterdam studies found 
improved performance if the ABI was used only in patients at intermediate risk. In all men 
and women combined, the NRI was 0.8% in the ARIC Study and 0.6% in the Rotterdam 
Study and, in those at intermediate risk, was 8.3% and 7.3%, respectively. A similar result 
(NRI 7.0%) was found in the elderly aged 70–79 years at intermediate risk in the Health, 
Aging and Body Composition Study.36 However, it has been pointed out recently that 
findings in intermediate groups may be overly optimistic due to possible bias in their 
estimation.37
Comparison with coronary artery calcium
In the Rotterdam Study, coronary artery calcium (CAC) showed better prediction than the 
ABI when added to a locally developed risk factor model.35 The NRIs for models in the 
whole population were 19.3% for CAC and 0.6% for ABI and, in those at intermediate risk, 
were 39.3% for CAC and 7.3% for ABI. Likewise in intermediate risk individuals in MESA, 
the NRI was much higher for CAC than for other measures of subclinical atherosclerosis 
including ABI.36 However, measurement of CAC is technically sophisticated, expensive, 
and involves radiation exposure,38 and so is less suited than the ABI to measurement in 
primary care or in population screening. The ABI can be measured easily with minimal 
training, using simple inexpensive equipment and in less than 15 min.39 A risk prediction 
programme incorporating measures of subclinical disease might benefit from tiered 
assessment with more complex and costly tests targeted on fewer individuals. Research is 
required on the costs and effectiveness of such an approach.
Limitations
A principal strength of this study was that, due to large numbers of subjects, models could 
be tested in both internal and external validation datasets derived from 18 population studies 
from several countries. A limitation of using multiple studies is that measurement of 
variables, including ABI, and the ascertainment and definition of endpoints were not 
identical. However, studies were only included where consistent and valid methods were 
used. Furthermore, using two study outcomes with hard endpoints (major coronary events 
and cardiovascular mortality) and finding broadly similar results, provided some reassurance 
on validity. Nevertheless, very large simulated datasets have been used as an alternative 
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approach to overcoming some of these difficulties.40 A further limitation of the study was 
that the exclusion criteria at baseline of only subjects with coronary heart disease meant that 
some subjects with other cardiovascular disease would be included, but were likely to make 
up a small proportion of the total population. Insufficient data were available to study non-
White populations.
The FRS applied in this study25 has been adopted in many practice settings but, more 
recently, the Framingham group produced a general cardiovascular disease risk factor model 
to be used in primary care for predicting a wider range of events.41 Due to limitations in our 
dataset, assessment of these outcomes was not feasible but, if predicting a wide range of 
events was desirable, evaluation of ABI risk models in this context would be useful, as 
would the contribution of the ABI to other risk models such as SCORE.42
Clinical implications
The ABI has been recognized for some time as potentially useful in screening healthy 
individuals for cardiovascular risk.43 However, guidelines have varied recommendations on 
use of the ABI. Recently, the US Preventive Services Task Force, while recognizing that use 
of the ABI would reclassify some men and women in the FRS intermediate risk category, 
considered the evidence insufficient to assess the benefits and harms, and concluded that 
clinical discretion was required.44 On the other hand, an American College of Cardiology 
Foundation/American Heart Association guideline included a recommendation, based on 
level of evidence B (nonrandomized studies), that ‘Measurement of ABI is reasonable for 
cardiovascular risk assessment in asymptomatic adults at intermediate risk’.45 Recent multi-
Society European guidelines had a similar recommendation.46 The results of our study 
provide some support for the use of an ABI risk model especially in individuals at 
intermediate risk and when performance of the base risk factor model is modest. 
Furthermore, if physicians are uncertain about how well the FRS performs in their practice, 
using the ABI model is likely to compensate for any deficiencies in the FRS.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Appendix 1: Studies, institutions, and investigators participating in the 
Ankle Brachial Index Collaboration
Co-ordinating centre University of Edinburgh
Isabella Butcher, Gerry 
Fowkes,
Gordon Murray
Atherosclerosis Risk in Communities 
Study
University of Minnesota Aaron Folsom, Alan Hirsch
University of North Carolina David Couper
Belgian Physical Fitness Study Ghent University Guy deBacker
University Libre de Bruxelles Marcel Kornitzer
Cardiovascular Health Study University of Pittsburgh Anne Newman, Kim Sutton-
Tyrrell*
University of Vermont Mary Cushman
Edinburgh Artery Study University of Aberdeen Amanda Lee
University of Edinburgh Gerry Fowkes, Jackie Price
Framingham Offspring Study Boston University Ralph d’Agostino, Joanne 
Murabito
Health ABC Study University of Pittsburgh Anne Newman, Kim Sutton-
Tyrrell*
Health in Men Study University of Western Australia Paul Norman
Honolulu Heart Program University of Hawaii Kamal Masaki
Hoorn Study VU University Amsterdam Lex Bouter, Robert Heine
Maastricht University Coen Stehouwer
InCHIANTI Study/Women’s Health and 
Aging Study
Northwestern University Feinberg 
School of Medicine
Mary McDermott
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Co-ordinating centre University of Edinburgh
Isabella Butcher, Gerry 
Fowkes,
Gordon Murray
Limburg PAOD Study Maastricht University Jelle Stoffers, Andre 
Knottnerus
Men born in 1914 Study University of Uppsala Mats Ogren
Lund University Bo Hedblad
MONICA Augsburg Study University of Ulm Wolfgang Koenig
Helmholtz Centrum Munich Christa Meisinger
Mr OS Study/Study of Osteoporotic 
Fractures
University of Pittsburgh Jane Cauley
Rotterdam Study Erasmus Medical Centre Oscar Franco, Albert Hofman, 
Myriam Hunink, Jacqueline 
Witteman,
San Diego Study University of California San Diego Michael Criqui
University of Nevada School of 
Medicine
Robert Langer
San Luis Valley Diabetes Study University of Colorado William Hiatt
Colorado School of Public Health Richard Hamman
*
deceased.
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Figure 1. Kaplan–Meier 10-year rates in men and women for major coronary events in risk 
categories predicted by the Framingham risk score with ankle brachial index and the 
Framingham risk score
Major coronary events are myocardial infarction and death due to coronary heart disease. 
Kaplan–Meier rates, derived from external validation dataset, are sometimes estimated from 
small numbers of events and may be imprecise. FRS, Framingham risk score; ABI, ankle 
brachial index.
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Table 2
C-indices for Framingham risk score predictions of major coronary events and cardiovascular mortality in men 
and women with and without the ankle brachial index for the development and internal and external validation 
datasets
Prediction model Development Internal validation External validation
Major coronary events
Men (n = 5632) (n = 5638) (n = 4962)
    FRS alone 0.715 (0.655–0.768) 0.721 (0.664–0.722) 0.672 (0.599–0.737)
    FRS+ABI 0.721 (0.661–0.773) 0.721 (0.664–0.722) 0.685 (0.612–0.749)
Women (n = 5869) (n = 5872) (n = 6459)
    FRS alone 0.661 (0.587–0.728) 0.676 (0.599–0.745) 0.578 (0.492–0.661)
    FRS+ABI 0.681 (0.607–0.746) 0.710 (0.633–0.775) 0.690 (0.605–0.764)
Cardiovascular mortality
Men (n = 6010) (n = 6016) (n = 12,349)
    FRS alone 0.809 (0.737–0.865) 0.794 (0.719–0.852) 0.684 (0.625–0.738)
    FRS+ABI 0.817 (0.746–0.872) 0.797 (0.723–0.855) 0.710 (0.652–0.762)
Women (n = 6339) (n = 6342) (n = 7696)
    FRS alone 0.568 (0.484–0.647) 0.604 (0.514–0.688) 0.449 (0.377–0.523)
    FRS+ABI 0.667 (0.585–0.740) 0.689 (0.600–0.765) 0.652 (0.579–0.719)
Values are C-index (95% CI); The number of subjects in major coronary events data sets are lower than in cardiovascular mortality datasets 
because of nonfatal events not ascertained in four studies in men (Health in Men, Mr Os, Hoorn, INCHIANTI) and three studies in women (Hoorn, 
InCHIANTI, Study of Osteoporotic Fractures); ABI, ankle brachial index; cardiovascular mortality, death due to coronary heart disease or stroke; 
FRS, Framingham risk score; major coronary event, myocardial infarction or death due to coronary heart disease.
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